Cronos Group (CRON) Aperçu de l'action
Cronos Group Inc. est une entreprise spécialisée dans les cannabinoïdes qui se consacre à la culture, à la production, à la distribution et à la commercialisation de produits à base de cannabis au Canada, en Israël et dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 2/6 |
| Croissance future | 4/6 |
| Performances passées | 0/6 |
| Santé financière | 6/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
Aucun risque n'a été détecté pour CRON à partir de nos contrôles de risques.
CRON Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
Read full narrativeCronos Group Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | CA$3.52 |
| Plus haut sur 52 semaines | CA$4.66 |
| Plus bas sur 52 semaines | CA$2.54 |
| Bêta | 1.23 |
| Variation sur 1 mois | 0.57% |
| Variation sur 3 mois | -2.22% |
| Variation sur 1 an | 26.62% |
| Variation sur 3 ans | 47.28% |
| Variation sur 5 ans | -59.63% |
| Évolution depuis l'introduction en bourse | 324.10% |
Nouvelles et mises à jour récentes
CRON: Partial Rescheduling Hopes Will Test Lean Cost Base Execution
Analysts have raised their Cronos Group price target to CA$4.50, citing expectations for slightly stronger revenue growth, modestly better profit margins, and a lower assumed future P/E, following recent bullish coverage and a favorable view on partial cannabis rescheduling. Analyst Commentary Recent research coverage on Cronos Group has centered on how potential regulatory shifts and brand positioning could influence the company’s path to improved profitability and valuation.
CRON: Canadian Brand Strength And Lean Cost Base Will Support Future Upside
Analysts have reset their price target for Cronos Group to CA$4.50, reflecting fresh coverage that highlights the company’s established Canadian brands, its focus on scaling revenue with a lean cost base, and cultivation practices that are expected to support profitability trends. Analyst Commentary Recent coverage frames Cronos Group as a company with established Canadian brands and a focus on keeping its cost base lean while scaling revenue.CRON: Lean Cost Base And Brand Execution Will Shape Future Earnings Potential
Analysts have lifted their average price target for Cronos Group to CA$4.50, citing expectations for faster top line expansion, a leaner cost base and stronger profitability potential supported by the company's established Canadian cannabis brands and cultivation practices. Analyst Commentary Recent Street research has framed Cronos Group as a branded cannabis operator with established products in Canada and an emphasis on scaling revenue while keeping operating costs in check.CRON: Canadian Brand Strength And Rescheduling Shift Will Support Future Upside
Analysts have lifted their CA$ price target on Cronos Group, citing the company's Canadian cannabis brands, expectations for better profitability as revenue grows against a lean cost base, and confidence in its cultivation practices as key supports for the higher valuation range. Analyst Commentary Bullish Takeaways Bullish analysts highlight Cronos Group's portfolio of Canadian cannabis brands as a key support for the higher CA$ valuation range, arguing that strong consumer recognition can help sustain revenue as the company scales.Recent updates
CRON: Partial Rescheduling Hopes Will Test Lean Cost Base Execution
Analysts have raised their Cronos Group price target to CA$4.50, citing expectations for slightly stronger revenue growth, modestly better profit margins, and a lower assumed future P/E, following recent bullish coverage and a favorable view on partial cannabis rescheduling. Analyst Commentary Recent research coverage on Cronos Group has centered on how potential regulatory shifts and brand positioning could influence the company’s path to improved profitability and valuation.CRON: Canadian Brand Strength And Lean Cost Base Will Support Future Upside
Analysts have reset their price target for Cronos Group to CA$4.50, reflecting fresh coverage that highlights the company’s established Canadian brands, its focus on scaling revenue with a lean cost base, and cultivation practices that are expected to support profitability trends. Analyst Commentary Recent coverage frames Cronos Group as a company with established Canadian brands and a focus on keeping its cost base lean while scaling revenue.CRON: Lean Cost Base And Brand Execution Will Shape Future Earnings Potential
Analysts have lifted their average price target for Cronos Group to CA$4.50, citing expectations for faster top line expansion, a leaner cost base and stronger profitability potential supported by the company's established Canadian cannabis brands and cultivation practices. Analyst Commentary Recent Street research has framed Cronos Group as a branded cannabis operator with established products in Canada and an emphasis on scaling revenue while keeping operating costs in check.CRON: Canadian Brand Strength And Rescheduling Shift Will Support Future Upside
Analysts have lifted their CA$ price target on Cronos Group, citing the company's Canadian cannabis brands, expectations for better profitability as revenue grows against a lean cost base, and confidence in its cultivation practices as key supports for the higher valuation range. Analyst Commentary Bullish Takeaways Bullish analysts highlight Cronos Group's portfolio of Canadian cannabis brands as a key support for the higher CA$ valuation range, arguing that strong consumer recognition can help sustain revenue as the company scales.CRON: Canadian Brand Strength And Rescheduling Shift Will Reshape Risk Reward Profile
Analysts have lifted their fair value estimate for Cronos Group to CA$4.24 from CA$3.95, pointing to higher assumed revenue growth and a lower future P/E multiple. They are factoring in recent bullish coverage highlighting the company’s established Canadian cannabis brands, lean cost base, and cultivation practices.CRON: Rescheduling Shift Will Expose Execution Risks And Restrain Earnings Upside
Analysts have lifted their CA$ fair value estimate for Cronos Group to CA$3.19, citing Street research that points to slightly higher expected revenue growth, modestly stronger profit margins, and a marginally lower future P/E assumption that together support a more constructive long term outlook. Analyst Commentary While the higher CA$3.19 fair value estimate reflects a more constructive stance on Cronos Group, not all research is leaning in the same direction.CRON: Rescheduling Shift And Product Expansion Will Shape A Balanced Earnings Outlook
Analysts have raised their price target on Cronos Group by a small amount to reflect updated assumptions for slightly higher revenue growth, a modestly stronger profit margin, and a marginally higher future P/E multiple. Analyst Commentary While some research points to a constructive view on Cronos Group, bearish analysts highlight a set of risks that could limit upside and keep the stock more range bound.CRON: Rescheduling Policy Shift Will Temper Optimism On Future Earnings Profile
Analysts have raised their price target for Cronos Group to US$3.19 from US$2.90, pointing to updated assumptions around slightly higher discount rates, more conservative revenue growth and a modestly stronger profit margin profile, alongside a similar forward P/E outlook. What's in the News President Trump directed the Attorney General to complete the rulemaking process to reschedule marijuana to Schedule III of the Controlled Substances Act, which directly touches U.S. cannabis policy and mentions Cronos Group among other publicly traded peers in the sector (Marijuana Herald).Cronos Group Inc. (TSE:CRON) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected
Cronos Group Inc. ( TSE:CRON ) shareholders have had their patience rewarded with a 29% share price jump in the last...GrowCo Capacity And Global Markets Will Unlock Potential
The Consensus Analyst Price Target for Cronos Group has increased to CA$3.95, primarily reflecting a notable rise in the company's Future P/E multiple despite stable revenue growth expectations. What's in the News President Trump is considering reclassifying marijuana as a less dangerous drug, which could ease restrictions and benefit cannabis companies such as Cronos Group (The Wall Street Journal).Cronos Group Inc.'s (TSE:CRON) 26% Share Price Surge Not Quite Adding Up
Cronos Group Inc. ( TSE:CRON ) shareholders would be excited to see that the share price has had a great month, posting...
GrowCo Expansion Will Boost Operations But Strain Cash Flow
Investment in GrowCo and advancements in cannabis genetics are set to improve efficiency, enhance profitability, and strengthen market penetration.We're Interested To See How Cronos Group (TSE:CRON) Uses Its Cash Hoard To Grow
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Cronos Group Inc.'s (TSE:CRON) P/S Is Still On The Mark Following 29% Share Price Bounce
The Cronos Group Inc. ( TSE:CRON ) share price has done very well over the last month, posting an excellent gain of...We Think Cronos Group (TSE:CRON) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Revenues Tell The Story For Cronos Group Inc. (TSE:CRON)
When you see that almost half of the companies in the Pharmaceuticals industry in Canada have price-to-sales ratios (or...Companies Like Cronos Group (TSE:CRON) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...We're Hopeful That Cronos Group (TSE:CRON) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...Cronos Group Inc.'s (TSE:CRON) Earnings Haven't Escaped The Attention Of Investors
When you see that almost half of the companies in the Pharmaceuticals industry in Canada have price-to-sales ratios (or...We Think Cronos Group (TSE:CRON) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Rendement pour les actionnaires
| CRON | CA Pharmaceuticals | CA Marché | |
|---|---|---|---|
| 7D | -2.8% | 1.6% | 1.0% |
| 1Y | 26.6% | 60.1% | 34.0% |
Rendement vs Industrie: CRON a sous-performé le secteur Canadian Pharmaceuticals qui a rapporté 59 % au cours de l'année écoulée.
Rendement vs marché: CRON a sous-performé le marché Canadian qui a rapporté 34.5 % au cours de l'année écoulée.
Volatilité des prix
| CRON volatility | |
|---|---|
| CRON Average Weekly Movement | 5.2% |
| Pharmaceuticals Industry Average Movement | 11.7% |
| Market Average Movement | 10.3% |
| 10% most volatile stocks in CA Market | 17.8% |
| 10% least volatile stocks in CA Market | 4.0% |
Cours de l'action stable: CRON n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché Canadian.
Volatilité au fil du temps: La volatilité hebdomadaire de CRON ( 5% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| n/a | 610 | Mike Gorenstein | thecronosgroup.com |
Cronos Group Inc. est une entreprise spécialisée dans les cannabinoïdes qui se consacre à la culture, à la production, à la distribution et à la commercialisation de produits à base de cannabis au Canada, en Israël et dans le monde entier. Elle propose des fleurs séchées, des pré-rouleaux, des huiles, des vaporisateurs, des produits comestibles et des teintures de cannabis sous les marques Spinach, Lord Jones et PEACE NATURALS. L'entreprise est basée à Stayner, au Canada.
Cronos Group Inc. Résumé des fondamentaux
| CRON statistiques fondamentales | |
|---|---|
| Capitalisation boursière | CA$1.35b |
| Bénéfices(TTM) | -CA$12.90m |
| Recettes(TTM) | CA$200.15m |
Le site CRON est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| CRON compte de résultat (TTM) | |
|---|---|
| Recettes | US$146.59m |
| Coût des recettes | US$88.19m |
| Marge brute | US$58.40m |
| Autres dépenses | US$67.85m |
| Les revenus | -US$9.45m |
Derniers bénéfices déclarés
Dec 31, 2025
Prochaine date de publication des résultats
May 11, 2026
| Résultat par action (EPS) | -0.025 |
| Marge brute | 39.84% |
| Marge bénéficiaire nette | -6.44% |
| Ratio dettes/capitaux propres | 0% |
Quelles ont été les performances à long terme de CRON?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/07 01:47 |
| Cours de l'action en fin de journée | 2026/05/07 00:00 |
| Les revenus | 2025/12/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Cronos Group Inc. est couverte par 16 analystes. 2 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Jesse Pytlak | ATB Cormark Historical (Cormark Securities) |
| Vahan Ajamian | Beacon Securities Limited |
| Nadine Sarwat | Bernstein |